Virginia Commonwealth University has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, myocardial infarction, arthritis, diabetes, gout, COVID-19, Alzheimer’s and Parkinson’s disease, among others.